Aetna modified CPB 1028 for difelikefalin (Korsuva) injection, effective January 5, 2026. Here's what billing teams need to know before submitting claims for this drug under commercial plans.
Aetna, a CVS Health company, updated its Korsuva coverage policy under CPB 1028 Aetna's clinical policy bulletin system. This change sets formal medical necessity criteria for HCPCS code J0879 and ties IV push administration codes CPT 96374–96379 to a strict set of hemodialysis-specific requirements. If your facility or nephrology practice administers difelikefalin during dialysis sessions, this policy governs whether Aetna pays.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Difelikefalin Injection (Korsuva) — CPB 1028 |
| Policy Code | CPB 1028 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | High |
| Specialties Affected | Nephrology, Dialysis Facilities, Infusion Billing Teams |
| Key Action | Confirm hemodialysis status, prior treatment failures, and nephrologist involvement before submitting J0879 claims |
Aetna Difelikefalin (Korsuva) Coverage Criteria and Medical Necessity Requirements 2026
The Aetna difelikefalin coverage policy requires precertification for all participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277 to start the process. You can also submit a Statement of Medical Necessity form through Aetna's Specialty Pharmacy Precertification portal.
This is not a drug where you bill and wait. Prior authorization is required up front, every time, for every member. Don't let your billing team submit J0879 without an auth number in hand.
Initial Approval: All Seven Criteria Must Be Met
Aetna considers difelikefalin (Korsuva) IV injection medically necessary only when a member meets all of the following criteria simultaneously:
| # | Covered Indication |
|---|---|
| 1 | Age: Member is 18 years or older. |
| 2 | Active hemodialysis: Member is currently undergoing hemodialysis (HD). Peritoneal dialysis doesn't qualify — see exclusions below. |
| 3 | Documented severity: Moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP), also called uremic pruritus, with baseline scoring. Aetna accepts the Worst Itching Intensity Numerical Rating Scale (WI-NRS), visual analog scale (VAS), or numeric rating scale (NRS). |
| 4 | Uremic cause confirmed: Pruritus must not come from non-uremic causes — no drug-induced hypersensitivity, allergies, dermatitis, psoriasis, liver disease, malignancy, lymphoma, post-herpetic neuralgia, or HIV. |
| 5 | Not dialysis-only symptoms: Pruritus must not be limited to occurring only during the dialysis session. If it only happens on the machine, Aetna won't cover it. |
| 6 | Prior treatment failures: Member must have tried and failed — or have a documented contraindication to — antihistamines, gabapentin, pregabalin, and topical emollients or analgesics. |
| 7 | Dose cap: 0.5 mcg/kg per HD treatment, no more than three doses per week. |
Every one of those seven boxes must be checked. Miss one, and you're looking at a claim denial. The step-therapy requirement (criterion six) is where most practices will run into trouble. Document those failed trials in the chart before you submit.
Prescriber Requirement
A nephrologist must prescribe or consult on this medication. A PCP or general internist ordering Korsuva on their own won't satisfy this criterion. Build the specialist involvement into your workflow before the precertification request goes out.
Continuation of Therapy
Reimbursement doesn't continue automatically. For ongoing therapy, the member must still meet all initial criteria and show documented clinical response — defined as at least a four-point improvement from baseline on the WI-NRS. If your provider can't produce that documentation, Aetna denies the continuation request.
This is a measurable threshold. Build the WI-NRS scoring into your dialysis unit's routine documentation. Don't let "the patient says they feel better" substitute for a number.
Aetna Korsuva Exclusions and Non-Covered Indications
Aetna will not cover difelikefalin injection for members on peritoneal dialysis. The policy is explicit: difelikefalin has not been studied in this population, so Aetna excludes it outright.
Any other indication beyond moderate-to-severe CKD-aP in adults undergoing hemodialysis is considered experimental, investigational, or unproven. There's no off-label pathway here for commercial members under this coverage policy.
If your patient is on peritoneal dialysis and has severe itch, difelikefalin billing under J0879 will not be covered. That's not a gray area. Don't submit it.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Moderate-to-severe CKD-aP in adults on hemodialysis, all 7 criteria met | Covered | J0879, L29.0–L29.9 + Z99.2, CPT 96374–96379 | Prior authorization required; nephrologist Rx required |
| CKD-aP in adults on peritoneal dialysis | Not Covered | — | Explicitly excluded; not studied in this population |
| Pruritus occurring only during dialysis sessions | Not Covered | — | Criterion five of initial approval is not met |
| Pruritus from non-uremic causes (dermatitis, psoriasis, liver disease, malignancy, HIV, etc.) | Not Covered | — | Criterion four of initial approval is not met |
| All other indications | Experimental / Investigational / Unproven | — | No off-label coverage under this commercial policy |
| Continuation of therapy without documented ≥4-point WI-NRS improvement | Not Covered | — | Continuation criterion two is not met |
Aetna Korsuva Billing Guidelines and Action Items 2026
The effective date is January 5, 2026. If you're billing difelikefalin for Aetna commercial members now, these steps apply immediately.
| # | Action Item |
|---|---|
| 1 | Add prior authorization to your Korsuva workflow before every claim. Precertification is mandatory for all Aetna participating providers. Call (866) 752-7021 or fax (888) 267-3277. No auth, no payment — it's that simple. |
| 2 | Pair J0879 with the correct ICD-10 codes. Bill Z99.2 (dependence on renal dialysis) alongside a code from L29.0–L29.9 for the pruritus. Aetna's policy explicitly requires Z99.2 to be billed with a code from that range. Submitting Z99.2 alone will cause a denial. |
| 3 | Document all six failed prior treatments in the chart before submitting. Antihistamines, gabapentin, pregabalin, and topical emollients or analgesics — Aetna wants to see that the member tried and failed these. Vague notes won't cut it. Date the trial periods and document why each was discontinued. |
| 4 | Capture baseline WI-NRS scores at the start of therapy. You'll need them for the initial approval, and you'll need them again for continuation. A four-point improvement from baseline is the continuation threshold. No baseline score means no measurable improvement, which means no continued coverage. |
| 5 | Confirm hemodialysis status — not peritoneal dialysis — before every auth request. Dialysis modality matters here. One word in the chart — "peritoneal" — means an automatic denial under this coverage policy. Verify the HD orders are current and in the record. |
| 6 | Enforce the dose cap in your charge capture. J0879 is billed per 0.1 mcg. The policy caps dosing at 0.5 mcg/kg per HD treatment, no more than three times weekly. If your charge capture doesn't enforce this, you risk overbilling. Audit your charge entry rules against these limits. |
| 7 | Verify nephrologist involvement before submitting. The prescribing or consulting nephrologist's NPI and documentation need to be in the record. If a non-nephrologist ordered this drug, the claim is vulnerable. |
If your dialysis facility handles a high volume of Korsuva administrations, talk to your compliance officer about whether your current documentation workflows meet these criteria. The specificity Aetna requires — scored severity, cause exclusions, prior treatment failures — means you need structured documentation, not free-text notes.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Difelikefalin (Korsuva) Under CPB 1028
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J0879 | HCPCS | Injection, difelikefalin, 0.1 microgram (for ESRD on dialysis) |
Key ICD-10-CM Diagnosis Codes
| Code | Description | Notes |
|---|---|---|
| L29.0 | Pruritus | Bill with Z99.2 |
| L29.1 | Pruritus | Bill with Z99.2 |
| L29.2 | Pruritus | Bill with Z99.2 |
| L29.3 | Pruritus | Bill with Z99.2 |
| L29.4 | Pruritus | Bill with Z99.2 |
| L29.5 | Pruritus | Bill with Z99.2 |
| L29.6 | Pruritus | Bill with Z99.2 |
| L29.7 | Pruritus | Bill with Z99.2 |
| L29.8 | Pruritus | Bill with Z99.2 |
| L29.9 | Pruritus, unspecified | Bill with Z99.2 |
| Z99.2 | Dependence on renal dialysis | Must be billed with a code from L29.0–L29.9 |
A note on those CPT codes: the policy lists 96374 through 96379 as "other CPT codes related to the CPB," not as separately covered injection add-ons. Your facility should confirm which specific IV push code applies to your administration scenario. If you're unsure which of these fits your charge capture setup, ask your billing consultant — the wrong administration code paired with J0879 is an easy denial to avoid.
Get the Full Picture for CPT 96374
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.